Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007


Worldwide Rights for All Potential Uses, Excluding U.S. and Japan

No Other Existing Therapeutic Treatment for Celiac Disease

BASINGSTOKE, England and PHILADELPHIA, December 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces that it has acquired the worldwide rights, excluding the U.S. and Japan, to AT-1001 from Alba Therapeutics Corporation (Alba). AT-1001 is Alba's lead inhibitor of barrier dysfunction in various gastrointestinal disorders that is currently in Phase 2 development for the treatment of Celiac disease. Shire has acquired rights to all uses for AT-1001, which may also be studied for the treatment of Crohn's disease and other indications.

Matthew Emmens, Chief Executive Officer, commented: "The licensing of AT-1001 from Alba is a natural fit to our growing portfolio of gastrointestinal products. This product will be marketed to specialist physicians and we would expect to use our existing European sales force that is currently establishing relationships and expertise in the GI area through the marketing of MEZAVANT XL."

Financial terms of the license are geared to the successful development and commercialization of the product. Shire will pay Alba an upfront license fee of $25 million and further development and sales-based milestones totalling to a maximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates.

Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-1001 has completed Proof of Concept, which is expected to be in the first half of 2009, after which Shire and Alba will share equally development costs under a joint development plan.

About Celiac disease:

Celiac disease is a T-cell mediated auto-immune dis
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic ... complete healing of an otherwise non-healing surgical knee wound. , The case involved ...
(Date:8/28/2015)... NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of FireflySci ... their quirky humor and excellent customer service. Images such as the Fonz in a ... to add some flavor to the humdrum spectroscopy field. , FireflySci is proud ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , a nationwide ... pleased to announce their ranking as one of the top 5000 companies listed on ... companies across the nation. , “It is truly an honor to be recognized as ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3
... Growing Generations, the nation,s,largest surrogacy agency, has launched ... to men with HIV and allows them to use,their ... program is made possible due to advances in technology ... the implementation of recent California,legislation enacted in January that ...
... 3 DermTech, a biotechnology,company developing molecular diagnostics ... today announced that Herbert A. Fritsche,Ph.D., has joined ... Chief of Clinical Chemistry at M.D. Anderson Cancer ... development and validation of cancer,diagnostics for early disease ...
... CORAL GABLES, Fla., June 3 Catalyst,Pharmaceutical ... biopharmaceutical company,that acquires, in-licenses, develops and commercializes ... and obsessive compulsive disorders,today announced the filing ... and Exchange Commission (SEC). After the shelf ...
Cached Biology Technology:Growing Generations Announces Surrogacy Program for Men with HIV 2DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board 2Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 2Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 3
(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/24/2015)... , August 24, 2015 The ... ,s largest biometrics manufacturer DERMALOG and its customized solutions ... "2015 African Biometrics Company of the Year Award". DERMALOG is ... Nigeria .   -Cross reference: Picture is ... - On Thursday evening, in ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... generation of cancer chemotherapeutic drugs specifically targets mutant enzymes ... uncontrolled cell growth. As promising as these drugs are, ... the tendency to fight back. A major goal of ... desperation. , In a forthcoming issue of Cancer Cell, ...
... Scientists have identified the first biochemical marker linked to sleep ... in activity when sleep deprivation is prolonged. , Researchers hope ... that will aid diagnosis and treatment of sleep disorders and ... at the wheel of a car or in other dangerous ...
... of these epidermal neural crest stem cells in the ... showing that these cells are distinctly different from other ... valuable resource for future mouse neural crest stem cell ... Maya Sieber-Blum's laboratory, co-authored by Yao Fei Hu, Ph.D., ...
Cached Biology News:Distinguishing friend from foe in the battle against cancer 2Distinguishing friend from foe in the battle against cancer 3First biomarker for human sleepiness identified in fruit flies 2First biomarker for human sleepiness identified in fruit flies 3Stem cells found in adult hair follicles may provide alternative to embryonic stem cells 2
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Homo sapiens palladin...
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: